HK Stock Market Move | ASCLETIS-B(01672) rises more than 7%. Positive results obtained from the single-dose escalation study of small molecule oral GLP-1R agonist ASC30 in the United States.

ASCLETIS-B (01672) surged more than 7%, reaching a 7.36% increase at the time of writing, at 4.23 Hong Kong dollars, with a trading volume of 5.68 million Hong Kong dollars. On the news side, ASCLETIS-B announced that the ASC30 oral tablets for the treatment of obese patients (body mass index (BMI): 30-40 kg/m2) in the United States single ascending dose (SAD) study (NCT06680440) have achieved positive top-line results. The SAD study consists of five cohorts (2 mg, 5 mg, 10 mg, 20 mg, and 40 mg) with a total of 40 obese patients, who undergo the study in a fasting state. ASC30 oral tablets showed good overall safety and tolerability in the Phase Ia SAD study. All adverse events (AE) were mild (Grade 1) or moderate (Grade 2), with most AEs related to gastrointestinal (GI) issues. There were no Grade 3 or above AEs, nor were there any serious adverse events (SAEs). The GI-related safety profile of ASC30 oral tablets is consistent with or better than other investigational small molecule oral GLP-1R agonists. In addition, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and other liver enzymes were within normal ranges. ASC30 is the first and only small molecule GLP-1R agonist for the treatment of obesity that can be administered subcutaneously once a month or orally once daily. Based on its pharmacokinetic and safety profile as well as its action on GLP-1R, ASC30 oral tablets are expected to become the best-in-class GLP-1R small molecule agonist.